Skip to content
TrialScanner

NCT04054921

Safety Study for Beta Thalassemia Subjects on PTG-300

Phase 2CompletedPTGXLead

Registry record

Lead sponsor
Protagonist Therapeutics, Inc.
Conditions
β-thalassemia; Ineffective Erythropoiesis
Primary completion
Jul 31, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04054921 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04054921: Safety Study for Beta... | TrialScanner